1. Home
  2. Analysis
  3. Keppra
  4. Tendon-injury

Keppra and Tendon injury - a phase IV clinical study of FDA data

Summary:

Tendon injury is reported as a side effect among people who take Keppra (levetiracetam), especially for people who are female, 50-59 old, also take Humira, and have Migraine.

The phase IV clinical study analyzes which people have Tendon injury when taking Keppra. It is created by eHealthMe based on reports of 70,297 people who have side effects when taking Keppra from the FDA, and is updated regularly.

What is Keppra?

Keppra has active ingredients of levetiracetam. It is often used in epilepsy. eHealthMe is studying from 73,504 Keppra users. Check the latest studies of Keppra.

What is Tendon injury?

Tendon injury is found to be associated with 433 drugs and 593 conditions by eHealthMe. Check the latest studies of Tendon injury.

On Jul, 19, 2026

70,297 people reported to have side effects when taking Keppra.
Among them, 11 people (0.02%) have Tendon injury.

Could Keppra cause Tendon injury?

Among these 11 people:

What is the gender of people who have Tendon injury when taking Keppra? *

  • female: 90.91 %
  • male: 9.09 %

What is the age of people who have Tendon injury when taking Keppra? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 10 %
  • 40-49: 40 %
  • 50-59: 50 %
  • 60+: 0.0 %

What are other drugs people take besides Keppra? *

  1. Humira: 5 people, 45.45%
  2. Synthroid: 4 people, 36.36%
  3. Sucralfate: 3 people, 27.27%
  4. Paxil: 3 people, 27.27%
  5. Folic Acid: 3 people, 27.27%
  6. Fiorinal: 3 people, 27.27%
  7. Famotidine: 3 people, 27.27%
  8. Elavil: 3 people, 27.27%
  9. Compazine: 3 people, 27.27%
  10. Clonazepam: 3 people, 27.27%

What are other side effects people have besides Tendon injury? *

  1. Skin Discoloration: 6 people, 54.55%
  2. Fall: 5 people, 45.45%
  3. Insomnia (sleeplessness): 4 people, 36.36%
  4. Dizziness: 4 people, 36.36%
  5. Tendon Disorder (disease of tendon): 4 people, 36.36%
  6. Hair Loss: 4 people, 36.36%
  7. Pain: 4 people, 36.36%
  8. Migraine (headache): 4 people, 36.36%
  9. Libido Decreased (loss of interest in sex): 4 people, 36.36%
  10. Memory Loss: 4 people, 36.36%

What are the existing conditions these people have? *

  1. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 4 people, 36.36%
  2. Migraine (headache): 4 people, 36.36%
  3. Nausea (feeling of having an urge to vomit): 3 people, 27.27%
  4. Sleep Disorder: 3 people, 27.27%
  5. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 3 people, 27.27%
  6. Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 3 people, 27.27%
  7. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 27.27%
  8. Abdominal Pain: 3 people, 27.27%
  9. Nausea And Vomiting: 3 people, 27.27%
  10. Pain: 3 people, 27.27%

* Approximation only. Some reports may have incomplete information.

Do you take Keppra and have Tendon injury?

- Check whether Tendon injury is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Keppra:

Tendon injury treatments and more:

How severe was Tendon injury and when was it recovered:

Expand to all the drugs that have ingredients of levetiracetam:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Keppra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Tendon injury:

Browse all the conditions that are associated with Tendon injury:

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on levetiracetam (the active ingredients of Keppra) and Keppra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.